Mirum Pharmaceuticals price target raised to $95 from $81 at Citizens JMP

Citizens JMP raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $95 from $81 and keeps an Outperform rating on the shares. Livmarli delivered another strong quarter of sales as focus is set to shift to the pivotal volixibat data in primary sclerosing cholangitis coming in the second half of 2026, the analyst tells investors in a research note. Mirum remains one of the firm’s favorite names in smid-cap biotech, with the stock up 70% year-to-date and poised for further growth on Livmarli’s commercial growth, path to profitability, and multiple late-stage clinical readouts starting next year in PSC.